title: Kallikrein gene transfer induces angiogenesis and further improves regional cerebral blood flow in the early period after cerebral ischemia/reperfusion in rats.
abstract: OBJECTIVE
  The aims of this study were to find out whether kallikrein could induce angiogenesis and affect the cerebral blood flow (rCBF) in the early period after cerebral ischemia/reperfusion (CI/R).
  
  
  METHODS
  The adenovirus carried human tissue kallikrein (HTK) gene was administrated into the periinfarction region after CI/R. At 12, 24, and 72 h after treatments, neurological deficits were evaluated; expression of HTK and vascular endothelial growth factor (VEGF) were detected by immunohistochemistry staining; the infarction volume was measured; and rCBF was examined by( 14) C-iodoantipyrine microtracing technique.
  
  
  RESULTS
  The expression of VEGF was enhanced significantly in pAdCMV-HTK group than controls over all time points (P < 0.05). Furthermore, the rCBF in pAdCMV-HTK group increased markedly than controls at 24 and 72 h after treatment (P < 0.05), and the improved neurological deficit was accompanied by reduced infarction volume in pAdCMV-HTK group 24 and 72 h posttreatment.
  
  
  CONCLUSIONS
  In the early period after CI/R, kallikrein could induce the angiogenesis and improve rCBF in periinfarction region, and further reduce the infarction volume and improve the neurological deficits.
authors.affiliation: Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Rui-Yan
authors.initials: RY
authors.lastname: Lu
authors.forename: Dan-Feng
authors.initials: DF
authors.lastname: Luo
authors.forename: Song-Hua
authors.initials: SH
authors.lastname: Xiao
authors.forename: Lian-Hong
authors.initials: LH
authors.lastname: Yang
authors.forename: Jia
authors.initials: J
authors.lastname: Zhao
authors.forename: Er-Ni
authors.initials: EN
authors.lastname: Ji
authors.forename: En-Xiang
authors.initials: EX
authors.lastname: Tao
authors.forename: Yi-Gang
authors.initials: YG
authors.lastname: Xing
authors.forename: Feng-Ying
authors.initials: FY
authors.lastname: Zhu
authors.forename: Ping
authors.initials: P
authors.lastname: Luan
authors.forename: Jun
authors.initials: J
authors.lastname: Liu
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000983:Antipyrine / Q000031:analogs & derivatives; D002247:Carbon Isotopes; D002544:Cerebral Infarction / Q000209:etiology / Q000473:pathology; D002560:Cerebrovascular Circulation / Q000235:genetics*; D004195:Disease Models, Animal; D005786:Gene Expression Regulation / Q000235:genetics; D018014:Gene Transfer Techniques; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000150:complications / Q000628:therapy*; D008297:Male; D018919:Neovascularization, Physiologic / Q000235:genetics* / Q000502:physiology; D009422:Nervous System Diseases / Q000209:etiology / Q000628:therapy; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000150:complications / Q000628:therapy*; D018709:Statistics, Nonparametric; D013997:Time Factors; D020840:Tissue Kallikreins / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002247:Carbon Isotopes; D042461:Vascular Endothelial Growth Factor A; D020840:Tissue Kallikreins; D000983:Antipyrine; C008135:iodoantipyrine